Safety and efficacy of Aromatase inhibitor for fertility treatment of young breast cancer patients.

Not Applicable

Recruiting

• Conditions: Breast cancer; C509

• Registration Number: JPRN-jRCTs031180419
• Lead Sponsor: Suzuki Nao

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-22
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

1, Diagnosed as Breast cancer with cytological or histological study
2, There is consult by letter from medical doctor who follow up the patient
3, Age 18 to 45 years-old
4, Expectable long-survival case
5, Written informed consent

Exclusion Criteria

1, After bilateral ovariectomy
2, The patients have past-history of ovarian cancer or cervical cancer(adenocarcinoma). If there are possibilities to get worse do to fertility treatment.
3, Pregnant women
4, During lactation
5, There are severe complications (e.g. uncontrollable DM, Auto immune disease which cause thrombosis easily, past history of thrombosis)
6, AST or ALT > 100U
7, BUN > 25mg/dl, or Cre > 2.0 mg/dl
8, The patients who are determined as ineligible cases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of recurrence, Birth abnormality.

Secondary Outcome Measures

Name	Time	Method
umber of extracted oocyte, fertilization rate, birth rate.